Cardiovascular mortality
Adaptive servo ventilation (ASV) plus best supportive care probably leads to higher cardiovascular mortality ‐ up to 80 months Number of participants:… compared with best supportive care alone or inactive control (moderate certainty).
1 finding from 1 review
RR 1.25 [1.04, 1.49]
Studies not reported
Moderate
Quality of life ‐ after 48 months Number of participants: 1325(1 RCT)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
AHI
1 finding from 1 review
no estimate extracted
Studies not reported
Low
All‐cause mortality ‐ up to 80 months Number of participants: 1355(2 RCTs)
Adaptive servo ventilation (ASV) plus best supportive care showed no clear difference in all‐cause mortality ‐ up to 80 months Number of participants: 1355(2… compared with best supportive care alone or inactive control (low certainty).
1 finding from 1 review
RR 0.56 [0.06, 4.93]
Studies not reported
Low
Exacerbations · patients with chronic obstructive pulmonary disease
PPI plus usual care may leads to lower exacerbation rate (participants with one or more) study duration: 12… compared with usual care alone or chronic obstructive pulmonary disease (low certainty).
1 finding from 1 review
Machine usage assessed by number of participants using machine for 4 or more hours per night ‐ not measured · adults with a diagnosis of sleep apnoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (machine tolerability outcomes) assessed as number of participants experiencing a blocked nose · adults with a diagnosis of sleep apnoea
Heated humidification + fixed CPAP may leads to lower adverse events (machine tolerability outcomes) assessed as number of… compared with fixed CPAP alone (low certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in quality of life: number of participants with clinically significant… compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher improvement in symptoms: number of participants with clinically… compared with aclidinium alone (high certainty).
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in adverse events (not including serious adverse events): number of… compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Intervention not reported
Exacerbation rates per participant per year · patients with COPD
The intervention probably leads to lower exacerbation rates per participant per year (moderate certainty).
1 finding from 1 review